Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice.
Identifieur interne : 001853 ( PubMed/Corpus ); précédent : 001852; suivant : 001854Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice.
Auteurs : Eun Kim ; Kaori Okada ; Tom Kenniston ; V Stalin Raj ; Mohd M. Alhajri ; Elmoubasher A B A. Farag ; Farhoud Alhajri ; Albert D M E. Osterhaus ; Bart L. Haagmans ; Andrea GambottoSource :
- Vaccine [ 1873-2518 ] ; 2014.
English descriptors
- KwdEn :
- Adenoviridae, Animals, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Antibody Formation, Camelus, Coronavirus Infections (prevention & control), HEK293 Cells, Humans, Immunoglobulin G (blood), Mice, Inbred BALB C, Middle East Respiratory Syndrome Coronavirus, Neutralization Tests, Spike Glycoprotein, Coronavirus (immunology), Viral Vaccines (immunology).
- MESH :
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral, Immunoglobulin G.
- chemical , immunology : Spike Glycoprotein, Coronavirus, Viral Vaccines.
- prevention & control : Coronavirus Infections.
- Adenoviridae, Animals, Antibody Formation, Camelus, HEK293 Cells, Humans, Mice, Inbred BALB C, Middle East Respiratory Syndrome Coronavirus, Neutralization Tests.
Abstract
A new type of coronavirus has been identified as the causative agent underlying Middle East Respiratory Syndrome (MERS). The MERS coronavirus (MERS-CoV) has spread in the Middle East, but cases originating in the Middle East have also occurred in the European Union and the USA. Eight hundred and thirty-seven cases of MERS-CoV infection have been confirmed to date, including 291 deaths. MERS-CoV has infected dromedary camel populations in the Middle East at high rates, representing an immediate source of human infection. The MERS-CoV spike (S) protein, a characteristic structural component of the viral envelope, is considered as a key target of vaccines against coronavirus infection. In an initial attempt to develop a MERS-CoV vaccine to ultimately target dromedary camels, we constructed two recombinant adenoviral vectors encoding the full-length MERS-CoV S protein (Ad5.MERS-S) and the S1 extracellular domain of S protein (Ad5.MERS-S1). BALB/c mice were immunized with both candidate vaccines intramuscularly and boosted three weeks later intranasally. All the vaccinated animals had antibody responses against spike protein, which neutralized MERS-CoV in vitro. These results show that an adenoviral-based vaccine can induce MERS-CoV-specific immune responses in mice and hold promise for the development of a preventive vaccine that targets the animal reservoir, which might be an effective measure to eliminate transmission of MERS-CoV to humans.
DOI: 10.1016/j.vaccine.2014.08.058
PubMed: 25192975
Links to Exploration step
pubmed:25192975Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice.</title>
<author><name sortKey="Kim, Eun" sort="Kim, Eun" uniqKey="Kim E" first="Eun" last="Kim">Eun Kim</name>
<affiliation><nlm:affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Okada, Kaori" sort="Okada, Kaori" uniqKey="Okada K" first="Kaori" last="Okada">Kaori Okada</name>
<affiliation><nlm:affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kenniston, Tom" sort="Kenniston, Tom" uniqKey="Kenniston T" first="Tom" last="Kenniston">Tom Kenniston</name>
<affiliation><nlm:affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Raj, V Stalin" sort="Raj, V Stalin" uniqKey="Raj V" first="V Stalin" last="Raj">V Stalin Raj</name>
<affiliation><nlm:affiliation>Department of Viroscience, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Alhajri, Mohd M" sort="Alhajri, Mohd M" uniqKey="Alhajri M" first="Mohd M" last="Alhajri">Mohd M. Alhajri</name>
<affiliation><nlm:affiliation>Supreme Council of Health, Doha, Qatar.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Farag, Elmoubasher A B A" sort="Farag, Elmoubasher A B A" uniqKey="Farag E" first="Elmoubasher A B A" last="Farag">Elmoubasher A B A. Farag</name>
<affiliation><nlm:affiliation>Supreme Council of Health, Doha, Qatar.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Alhajri, Farhoud" sort="Alhajri, Farhoud" uniqKey="Alhajri F" first="Farhoud" last="Alhajri">Farhoud Alhajri</name>
<affiliation><nlm:affiliation>Animal Resources Department - Ministry of Environment, Doha, Qatar.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D M E" last="Osterhaus">Albert D M E. Osterhaus</name>
<affiliation><nlm:affiliation>Department of Viroscience, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L" last="Haagmans">Bart L. Haagmans</name>
<affiliation><nlm:affiliation>Department of Viroscience, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gambotto, Andrea" sort="Gambotto, Andrea" uniqKey="Gambotto A" first="Andrea" last="Gambotto">Andrea Gambotto</name>
<affiliation><nlm:affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA. Electronic address: gambottoa@upmc.edu.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25192975</idno>
<idno type="pmid">25192975</idno>
<idno type="doi">10.1016/j.vaccine.2014.08.058</idno>
<idno type="wicri:Area/PubMed/Corpus">001853</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001853</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice.</title>
<author><name sortKey="Kim, Eun" sort="Kim, Eun" uniqKey="Kim E" first="Eun" last="Kim">Eun Kim</name>
<affiliation><nlm:affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Okada, Kaori" sort="Okada, Kaori" uniqKey="Okada K" first="Kaori" last="Okada">Kaori Okada</name>
<affiliation><nlm:affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kenniston, Tom" sort="Kenniston, Tom" uniqKey="Kenniston T" first="Tom" last="Kenniston">Tom Kenniston</name>
<affiliation><nlm:affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Raj, V Stalin" sort="Raj, V Stalin" uniqKey="Raj V" first="V Stalin" last="Raj">V Stalin Raj</name>
<affiliation><nlm:affiliation>Department of Viroscience, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Alhajri, Mohd M" sort="Alhajri, Mohd M" uniqKey="Alhajri M" first="Mohd M" last="Alhajri">Mohd M. Alhajri</name>
<affiliation><nlm:affiliation>Supreme Council of Health, Doha, Qatar.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Farag, Elmoubasher A B A" sort="Farag, Elmoubasher A B A" uniqKey="Farag E" first="Elmoubasher A B A" last="Farag">Elmoubasher A B A. Farag</name>
<affiliation><nlm:affiliation>Supreme Council of Health, Doha, Qatar.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Alhajri, Farhoud" sort="Alhajri, Farhoud" uniqKey="Alhajri F" first="Farhoud" last="Alhajri">Farhoud Alhajri</name>
<affiliation><nlm:affiliation>Animal Resources Department - Ministry of Environment, Doha, Qatar.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D M E" last="Osterhaus">Albert D M E. Osterhaus</name>
<affiliation><nlm:affiliation>Department of Viroscience, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L" last="Haagmans">Bart L. Haagmans</name>
<affiliation><nlm:affiliation>Department of Viroscience, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gambotto, Andrea" sort="Gambotto, Andrea" uniqKey="Gambotto A" first="Andrea" last="Gambotto">Andrea Gambotto</name>
<affiliation><nlm:affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA. Electronic address: gambottoa@upmc.edu.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenoviridae</term>
<term>Animals</term>
<term>Antibodies, Neutralizing (blood)</term>
<term>Antibodies, Viral (blood)</term>
<term>Antibody Formation</term>
<term>Camelus</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>HEK293 Cells</term>
<term>Humans</term>
<term>Immunoglobulin G (blood)</term>
<term>Mice, Inbred BALB C</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Neutralization Tests</term>
<term>Spike Glycoprotein, Coronavirus (immunology)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
<term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adenoviridae</term>
<term>Animals</term>
<term>Antibody Formation</term>
<term>Camelus</term>
<term>HEK293 Cells</term>
<term>Humans</term>
<term>Mice, Inbred BALB C</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Neutralization Tests</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A new type of coronavirus has been identified as the causative agent underlying Middle East Respiratory Syndrome (MERS). The MERS coronavirus (MERS-CoV) has spread in the Middle East, but cases originating in the Middle East have also occurred in the European Union and the USA. Eight hundred and thirty-seven cases of MERS-CoV infection have been confirmed to date, including 291 deaths. MERS-CoV has infected dromedary camel populations in the Middle East at high rates, representing an immediate source of human infection. The MERS-CoV spike (S) protein, a characteristic structural component of the viral envelope, is considered as a key target of vaccines against coronavirus infection. In an initial attempt to develop a MERS-CoV vaccine to ultimately target dromedary camels, we constructed two recombinant adenoviral vectors encoding the full-length MERS-CoV S protein (Ad5.MERS-S) and the S1 extracellular domain of S protein (Ad5.MERS-S1). BALB/c mice were immunized with both candidate vaccines intramuscularly and boosted three weeks later intranasally. All the vaccinated animals had antibody responses against spike protein, which neutralized MERS-CoV in vitro. These results show that an adenoviral-based vaccine can induce MERS-CoV-specific immune responses in mice and hold promise for the development of a preventive vaccine that targets the animal reservoir, which might be an effective measure to eliminate transmission of MERS-CoV to humans. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25192975</PMID>
<DateCompleted><Year>2015</Year>
<Month>04</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>32</Volume>
<Issue>45</Issue>
<PubDate><Year>2014</Year>
<Month>Oct</Month>
<Day>14</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice.</ArticleTitle>
<Pagination><MedlinePgn>5975-82</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2014.08.058</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0264-410X(14)01199-2</ELocationID>
<Abstract><AbstractText>A new type of coronavirus has been identified as the causative agent underlying Middle East Respiratory Syndrome (MERS). The MERS coronavirus (MERS-CoV) has spread in the Middle East, but cases originating in the Middle East have also occurred in the European Union and the USA. Eight hundred and thirty-seven cases of MERS-CoV infection have been confirmed to date, including 291 deaths. MERS-CoV has infected dromedary camel populations in the Middle East at high rates, representing an immediate source of human infection. The MERS-CoV spike (S) protein, a characteristic structural component of the viral envelope, is considered as a key target of vaccines against coronavirus infection. In an initial attempt to develop a MERS-CoV vaccine to ultimately target dromedary camels, we constructed two recombinant adenoviral vectors encoding the full-length MERS-CoV S protein (Ad5.MERS-S) and the S1 extracellular domain of S protein (Ad5.MERS-S1). BALB/c mice were immunized with both candidate vaccines intramuscularly and boosted three weeks later intranasally. All the vaccinated animals had antibody responses against spike protein, which neutralized MERS-CoV in vitro. These results show that an adenoviral-based vaccine can induce MERS-CoV-specific immune responses in mice and hold promise for the development of a preventive vaccine that targets the animal reservoir, which might be an effective measure to eliminate transmission of MERS-CoV to humans. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Eun</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Okada</LastName>
<ForeName>Kaori</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kenniston</LastName>
<ForeName>Tom</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Raj</LastName>
<ForeName>V Stalin</ForeName>
<Initials>VS</Initials>
<AffiliationInfo><Affiliation>Department of Viroscience, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>AlHajri</LastName>
<ForeName>Mohd M</ForeName>
<Initials>MM</Initials>
<AffiliationInfo><Affiliation>Supreme Council of Health, Doha, Qatar.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Farag</LastName>
<ForeName>Elmoubasher A B A</ForeName>
<Initials>EA</Initials>
<AffiliationInfo><Affiliation>Supreme Council of Health, Doha, Qatar.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>AlHajri</LastName>
<ForeName>Farhoud</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Animal Resources Department - Ministry of Environment, Doha, Qatar.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Osterhaus</LastName>
<ForeName>Albert D M E</ForeName>
<Initials>AD</Initials>
<AffiliationInfo><Affiliation>Department of Viroscience, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Haagmans</LastName>
<ForeName>Bart L</ForeName>
<Initials>BL</Initials>
<AffiliationInfo><Affiliation>Department of Viroscience, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gambotto</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA. Electronic address: gambottoa@upmc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 CA047904</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000256" MajorTopicYN="Y">Adenoviridae</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002162" MajorTopicYN="N">Camelus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="Y">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adenoviral vaccines</Keyword>
<Keyword MajorTopicYN="N">Codon-optimized</Keyword>
<Keyword MajorTopicYN="N">MERS-CoV S</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>05</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2014</Year>
<Month>08</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>08</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>9</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>9</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25192975</ArticleId>
<ArticleId IdType="pii">S0264-410X(14)01199-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2014.08.058</ArticleId>
<ArticleId IdType="pmc">PMC7115510</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2014 Apr;20(4):552-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24655412</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2004 Sep 15;190(6):1119-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15319862</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2013 Nov 28;369(22):2083-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24099601</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hepatology. 2004 Feb;39(2):302-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14767982</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1990 Mar;64(3):1407-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2154621</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2013 Aug;87(16):9379-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23785207</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Vaccine Immunol. 2010 Sep;17(9):1467-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20660133</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2014 May;88(9):5100-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24574396</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Pathol. 2007 Apr;170(4):1136-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17392154</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Curr. 2013 Nov 12;5:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24270606</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2005 Sep;112(1-2):24-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16022898</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet Infect Dis. 2014 Feb;14(2):93-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24355867</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet Infect Dis. 2013 Oct;13(10):859-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23933067</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2014 Aug;20(8):1339-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25075761</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Microbiol. 2004 Feb;2(2):109-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15043007</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2122-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15220033</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2008 Feb 5;371(1):32-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17961624</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Expert Rev Vaccines. 2003 Jun;2(3):399-406</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12903805</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2006 Jun 29;24(26):5498-508</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16725238</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Mar;79(5):2678-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15708987</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2013 Dec 04;8(12):e81587</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24324708</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2002 Jan 17;415(6869):331-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11797011</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Comp Immunol Microbiol Infect Dis. 1981;4(2):175-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6754243</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet Infect Dis. 2014 Feb;14(2):140-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24355866</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 2005 Dec 19;579(30):6699-704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16310778</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2013 Nov;87(21):11950-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23986586</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2005 Mar 30;334(1):74-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15749124</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2013 Nov 11;8(11):e78679</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24244339</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Annu Rev Med. 2004;55:355-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14746526</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1997 Mar;71(3):1842-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9032314</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Trends Microbiol. 2004 Oct;12(10):466-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15381196</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Nov;78(22):12672-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15507655</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Euro Surveill. 2013 Dec 12;18(50):20662</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24342516</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2273-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15755610</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2006 Feb;80(4):1959-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16439551</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 2006 Jan;87(Pt 1):139-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16361426</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 Aug 7;424(6949):681-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12904795</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Microbiol. 2013 Dec;11(12):836-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24217413</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2010 May 05;5(5):e10492</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20463955</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>mBio. 2012 Nov 20;3(6):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23170002</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Gene Ther. 2005 Oct;12 Suppl 1:S73-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16231058</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Dec 6;362(9399):1895-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14667748</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Vaccine Immunol. 2012 Nov;19(11):1722-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22933397</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Mol Immunol. 2004 Apr;1(2):119-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16212898</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Transl Med. 2013 Oct 2;5(205):205ra134</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24089406</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Expert Opin Biol Ther. 2010 Oct;10(10):1469-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20822477</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2006 Dec 20;1:e24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17183651</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biotechnol Prog. 2004 Mar-Apr;20(2):443-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15058988</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001853 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001853 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:25192975 |texte= Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25192975" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |